Delhi HC set to rule on Daiichi Sankyo arbitration case
The Delhi High Court is expected to rule this week on Daiichi Sankyo’s long-running arbitration dispute with former Fortis promoters Malvinder and Shivinder Singh. The Singapore arbitration award, linked to the 2008 Ranbaxy sale, has risen to abou...

Former Fortis promoters Malvinder and Shivinder Singh
Japanese drugmaker Daiichi Sankyo is seeking enforcement of an arbitration award in its favour against former Fortis promoters Malvinder and Shivinder Mohan Singh over alleged fraud in the 2008 sale of their pharma company Ranbaxy Laboratories to the Japanese firm. Including interest, the amount awarded by a Singapore tribunal a decade ago has now swelled to ₹5,200 crore.
To secure payment, Daiichi wanted to prevent the Singh brothers from diluting their stake in Fortis, but lenders invoked and sold the brothers' pledged shares to recover debt. The case has effectively become a three-way contest among the Singh brothers, lenders and Fortis over who bears responsibility for shrinking assets of Singh brothers.
Daiichi, represented by senior advocate Arvind Nigam and advocate Giriraj Subramanium, questioned deals involving Fortis' stake, including sale of 186 million encumbered shares, terming them deliberate asset.
"18.6 crore shares were encumbered by financial institutions and banks-disclosures made, uploaded by the company and sold, leaving 13.99 crore shares, which were unencumbered and sold in transactions with the approval of the compliance officer at a point of time when the FHL was an entity of the judgment debtors," Nigam argued before the bench of Justice Subramonium Prasad.
During the last hearing, Fortis counsel said that "FHL and its compliance officer never gave any approval to any of these transfers".
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.